Keros Therapeutics Inc
KROS16.200USD
+0.030+0.19%
收盘 11/07, 16:00（美东）报价延迟15分钟
658.24M总市值
10.21市盈率 TTM
关于 Keros Therapeutics Inc 公司
Keros Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发和商业化新型疗法，以治疗一系列与转化生长因子-β (TGF-B) 蛋白家族信号传导功能障碍相关的疾病患者。该公司的主要候选产品 KER-050 正在开发中，用于治疗骨髓增生异常综合征患者和骨髓纤维化患者的低血细胞计数或血细胞减少症（包括贫血和血小板减少症）。该公司的第二个候选产品 KER-012 正在开发中，用于治疗肺动脉高压 (PAH) 和心血管疾病。该公司的第三个候选产品 KER-065 正在开发中，用于治疗肥胖症和神经肌肉疾病。KER-050 旨在通过抑制 TGF-B 蛋白家族子集的信号传导来促进造血，从而增加红细胞和血小板的生成。
Keros Therapeutics Inc简介
公司代码KROS
公司名称Keros Therapeutics Inc
上市日期Apr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
员工数量169
证券类型Ordinary Share
年结日Apr 08
公司地址1050 Waltham Street, Suite 302
城市LEXINGTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02421
电话16173146297
网址https://www.kerostx.com/
公司代码KROS
上市日期Apr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
Keros Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+29.94%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. Alpna Hansraj Seth, Ph.D.
Dr. Alpna Hansraj Seth, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lorena Lerner, Ph.D.
Dr. Lorena Lerner, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+29.94%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月18日 周六
更新时间: 10月18日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.89%
Madison Avenue Partners LP
8.83%
Tang Capital Management, LLC
7.94%
BlackRock Institutional Trust Company, N.A.
7.85%
Logos Global Management LP
6.56%
其他
59.93%
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.89%
Madison Avenue Partners LP
8.83%
Tang Capital Management, LLC
7.94%
BlackRock Institutional Trust Company, N.A.
7.85%
Logos Global Management LP
6.56%
其他
59.93%
股东类型
持股股东
占比
Hedge Fund
28.22%
Investment Advisor
20.16%
Investment Advisor/Hedge Fund
16.87%
Venture Capital
5.08%
Research Firm
4.48%
Private Equity
2.51%
Corporation
1.41%
Individual Investor
1.35%
Pension Fund
1.12%
其他
18.79%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
385
41.03M
124.11%
-17.81M
2025Q2
392
46.16M
114.02%
-7.54M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
2023Q3
303
31.04M
104.70%
-2.97M
2023Q2
305
30.88M
104.58%
-2.59M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
2.62M
6.45%
+53.89K
+2.10%
Jun 30, 2025
Madison Avenue Partners LP
2.69M
6.63%
+77.06K
+2.95%
Jun 30, 2025
Tang Capital Management, LLC
1.42M
3.49%
+318.98K
+29.00%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.39M
5.88%
-118.03K
-4.71%
Jun 30, 2025
Logos Global Management LP
2.00M
4.92%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
1.62M
3.99%
+113.90K
+7.56%
Jun 30, 2025
D. E. Shaw & Co., L.P.
1.30M
3.19%
+34.25K
+2.71%
Jun 30, 2025
Western Standard, LLC
1.53M
3.78%
+1.40M
+1037.68%
Jun 30, 2025
State Street Investment Management (US)
1.38M
3.41%
+81.72K
+6.27%
Jun 30, 2025
OrbiMed Advisors, LLC
1.02M
2.51%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.84%
ALPS Medical Breakthroughs ETF
0.38%
Federated Hermes MDT Small Cap Core ETF
0.21%
SPDR S&P Biotech ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
WisdomTree US SmallCap Quality Growth Fund
0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
iShares Biotechnology ETF
0.05%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.84%
ALPS Medical Breakthroughs ETF
占比0.38%
Federated Hermes MDT Small Cap Core ETF
占比0.21%
SPDR S&P Biotech ETF
占比0.18%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.1%
WisdomTree US SmallCap Quality Growth Fund
占比0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.07%
Invesco Nasdaq Biotechnology ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
iShares Biotechnology ETF
占比0.05%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
